Switching From ART To Single-Tablet Doravirine-Islatravir Noninferior For HIV Suppression, Study Finds

Infectious Disease Advisor (6/21, Nye) reported, “Switching from antiretroviral therapy (ART) combinations to single-tablet doravirine plus islatravir is noninferior for HIV virologic suppression but may lead to reductions in CD4+ cell and total lymphocyte counts. These findings, from 2 phase 3 companion trials, were published in The Lancet HIV.” In the first trial, researchers “observed HIV-1 RNA measurements at or above 50 copies/mL among 0% of patients who switched regimens and 1.5% of those who continued their baseline regimens (mean difference [MD], -1.5%; 95% CI, -3.4 to -0.3), indicating noninferiority.” In the second trial, investigators “observed noninferiority between the groups in the second trial, with HIV-1 RNA measurements at or above 50 copies/mL in 0.6% of those who switched regimens and 0.3% of those who continued their baseline regimen (MD, 0.3%; 95% CI, -1.2 to 2.0).”